Melanotan ICosmetic / Skin
First-generation melanocortin agonist studied for skin pigmentation.
- Status
- Prescription
- Developer
- University of Arizona; afamelanotide / Scenesse (Clinuvel)
- Receptors / target
- Melanocortin-1 receptor (MC1R) agonist; a stable synthetic analog of alpha-MSH that stimulates eumelanin synthesis for photoprotection
- FDA-approved?
- YES
- Prescription available?
- YES
- Studied for
- skin pigmentation / melanogenesisphotoprotectionerythropoietic protoporphyria (EPP)photodermatoses
Overview
Melanotan I — generic name afamelanotide (also NDP-alpha-MSH), brand Scenesse — is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH). Two realities must be kept separate: as Scenesse, a controlled-release subcutaneous implant made by Clinuvel, afamelanotide is FDA-approved (2019) to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria (EPP), a rare inherited disorder. The same peptide sold as a "research" or "tanning" injectable is the identical molecule but is not an approved product for cosmetic tanning and carries no regulatory oversight for that use.
Mechanism
Afamelanotide is a potent, metabolically stable MC1R agonist whose receptor binding is more durable than native alpha-MSH. Activation of MC1R on melanocytes drives synthesis of eumelanin, the brown-black pigment that provides photoprotection by absorbing and scattering light — and, critically, it raises melanin density without the UV-induced DNA damage that accompanies sun-driven tanning. In EPP, this added shielding reduces the phototoxicity caused by accumulated protoporphyrin IX.
Clinical evidence
Human evidence is strong and specific to EPP. Pivotal data come from multicenter, randomized, double-blind, vehicle-controlled trials (EU n=74, US n=94; Langendonk et al., NEJM 2015) showing that 16 mg implants every 60 days increased pain-free sunlight exposure and improved quality of life, and a long-term observational cohort (Biolcati et al., 2015) followed 115 patients across 1,023 implants over up to 8 years with sustained benefit and good safety. Evidence for the popular "tanning" use is anecdotal — no rigorous human trials support unsupervised cosmetic injection.
Safety profile
In the approved EPP setting the safety profile is well characterized and generally favorable. The most common adverse reactions are implant-site reactions, nausea, oropharyngeal pain, cough and fatigue, plus skin hyperpigmentation; afamelanotide can also darken pre-existing moles and freckles, so twice-yearly full-body skin examinations are recommended, and serious hypersensitivity reactions including anaphylaxis have been reported post-approval. Research-grade injectable "melanotan I" for tanning bypasses the implant's controlled dosing, medical monitoring and pharmaceutical-grade purity — adding unverified-product and dosing risks. Nothing here is a treatment recommendation outside the approved Scenesse indication.
- Days to weeks
Increased eumelanin/skin pigmentation develops over days to a couple of weeks; the approved Scenesse implant is given every ~2 months for EPP photoprotection.
- Ongoing
The photoprotective effect persists while dosing continues and fades after stopping. Darkening of moles/freckles can occur and warrants skin monitoring.
Reported in published literature and user reports. Not a complete list, and not medical advice.
- Nausea
- Facial flushing
- Darkening of moles / new nevi
- Headache
- Injection-site reactions
If severe or unexpected symptoms occur, contact a qualified medical professional. PEPTIDES·INDEX does not provide medical advice.
- History of melanoma or changing/atypical moles — melanocortin agonism can darken nevi; close dermatologic monitoring is warranted (use the approved Scenesse implant only under supervision)
- Known hypersensitivity to afamelanotide — serious hypersensitivity reactions including anaphylaxis have been reported post-approval
- No well-characterized drug-drug interactionsThe Scenesse label does not establish significant drug interactions; the interaction profile of injectable research-grade melanotan I is uncharacterized in humans
Compare
- vs Melanotan II
The non-selective, unlicensed sibling with documented harms (priapism, rhabdomyolysis, melanoma reports); melanotan I (afamelanotide) is the MC1R-selective, FDA-approved-for-EPP compound
FAQ
Is Melanotan I FDA-approved?
Yes, but only in a specific form. As afamelanotide (brand Scenesse), a controlled-release subcutaneous implant, it is FDA-approved to increase pain-free light exposure in adults with erythropoietic protoporphyria (EPP). The injectable sold for cosmetic tanning is the same molecule but is not an approved product for that use and has no regulatory oversight.
Is Melanotan I safe for tanning?
There are no rigorous human trials supporting unsupervised cosmetic injection. The approved EPP implant is medically monitored, controlled-dose and pharmaceutical-grade; research-grade tanning injectables bypass all of that and add unverified-product and dosing risks.
Can Melanotan I affect moles or skin cancer risk?
Afamelanotide can darken pre-existing moles and freckles, which is why twice-yearly full-body skin examinations are recommended in the approved setting. Anyone with melanoma or changing/atypical moles should approach melanocortin agonists with particular caution and dermatologic monitoring.
How does Melanotan I differ from Melanotan II?
Melanotan I (afamelanotide) is a linear, MC1R-selective alpha-MSH analog that is FDA-approved as the Scenesse implant for erythropoietic protoporphyria. Melanotan II is a cyclic, non-selective melanocortin agonist (MC1R through MC5R) that is unlicensed and tied to harms like priapism and rhabdomyolysis. The added MC4R/MC3R activity of Melanotan II is why it also affects libido and appetite, while Melanotan I is more pigment-specific.
How is approved Melanotan I (Scenesse) given?
Scenesse is a controlled-release dissolvable implant about the size of a grain of rice, inserted subcutaneously above the hip by a trained physician roughly every two months during periods of high light exposure. This is very different from the self-injected research-grade vials sold for tanning.
Does Melanotan I actually produce a tan?
It stimulates eumelanin, the brown-black pigment, so it can darken skin without UV-induced DNA damage. But that cosmetic use is unapproved and unstudied in rigorous human trials, and the only evidence-backed indication is photoprotection in EPP. Pigmentation fades after dosing stops.
Similar compounds
Starting references for the library summary. These are not dosing instructions or medical advice.
For research-use educational context only. Not medical advice and not a recommendation to use any compound. Consult a qualified healthcare professional before any health decision.